comparemela.com

Latest Breaking News On - Magicmed industries - Page 8 : comparemela.com

Another Psychedelics Company Joins Exclusive Nasdaq Group With Enveric s Acquisition Of MagicMed Industries

MagicMed Industries in an all-stock deal. What Happened It s been in the works for a little while, Dr. Joseph Tucker, CEO and president of MagicMed, told Benzinga. According to Tucker, listing on the Nasdaq provides companies with an attractive opportunity for raising capital. It s a really exclusive group listed on the Nasdaq, and that access to capital is going to be a game-changer for everybody, Tucker said. Upon closing the acquisition, Tucker will become CEO at the new company and David Johnson, current CEO and chairman, will become executive chairman. Why It Matters – ‘Like Two Halves Of One Company’ MagicMed Industries is researching second-generation psychedelic molecules with the aim of developing medicine for various mental health conditions. It is currently studying novel molecules derived from psilocybin,

MagicMed: The Psychedelics Patent Debate

.  “The risk of going through those processes as required by law is extremely high. And if there’s no way for investors to recover their investment, then they won’t fund it. And then these drugs, which might be lifesaving drugs, will never get approved and society will never benefit from them. So there’s a value to patents,” says Dr. Joseph Tucker, CEO of MagicMed, a company developing second-generation psychedelics. The article explains that If a company obtains several strong and important patents, it can leverage them to prevent competition. However, many of the molecules being researched today in the psychedelics space either exist in nature or are old enough to be public domain.

MariMed Inc : MagicMed Industries to present at the Planet MicroCap Showcase: Virtual on April 22nd

MariMed Inc.: MagicMed Industries to present at the Planet MicroCap Showcase: Virtual on April 22nd MagicMed Industries Inc. ( MagicMed or the Company ), a biotechnology company focused on creating novel psychedelic derivative molecules, today announced that Dr. Joseph Tucker, President and Chief Executive Officer, will be presenting a business and pipeline update at the LifeSciencesInvestorForum.com on April 22 nd, 2021 as follows: LINK: https://www.webcaster4.com/Webcast/Page/2059/40839 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, and archived webcast will also me made available after the event.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.